KDM5B and breast carcinoma: Another study suggests that lysine demethylase (KDM5B), a novel regulator of lipid metabolism reprogramming, reduced the protein levels of fatty acid synthase (FASN) and ATP citrate lyase (ACLY) and was up-regulated in breast cancer, and that activation of the AMPK signalling pathway was involved in KDM5B-mediated reprogramming of lipid metabolism in breast cancer cells, making it A new strategy for the treatment of breast cancer [129].